REPLIMUNE GROUP, INC. Current Assets
REPLIMUNE GROUP, INC. (REPL) had Current Assets of $200.81 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-14
- 2026-06-30: Assets, Current $200.81M.
- 2026-03-31: Assets, Current $279.12M.
- 2025-12-31: Assets, Current $280.35M.
- 2025-09-30: Assets, Current $333.75M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $200.81M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $279.12M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $280.35M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $333.75M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $413.37M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $495.88M 10-K · filed 2026-06-29 |
| 2024-12-31 | $547.58M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $442.63M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $480.32M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $433.67M 10-K · filed 2025-05-22 |
| 2023-12-31 | $479.16M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $508.18M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $550.04M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $592.60M 10-K · filed 2024-05-16 |
| 2022-12-31 | $623.96M 10-Q · filed 2023-02-09 |
| 2022-09-30 | $379.39M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $401.95M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $403.98M 10-K · filed 2023-05-18 |
| 2021-12-31 | $427.80M 10-Q · filed 2022-02-03 |
| 2021-09-30 | $444.38M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $464.56M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $483.75M 10-K · filed 2022-05-19 |
| 2020-12-31 | $499.43M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $252.41M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $267.74M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $174.25M 10-K · filed 2021-05-20 |
| 2019-12-31 | $190.87M 10-Q · filed 2020-02-13 |
| 2019-09-30 | $118.01M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $127.74M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $140.98M 10-K · filed 2020-06-03 |
| 2018-12-31 | $144.95M 10-Q · filed 2019-02-14 |
| 2018-09-30 | $151.87M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $55.22M 10-Q · filed 2018-08-30 |
| 2018-03-31 | $64.70M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |